https://doi.org/10.4081/monaldi.2022.2284
Role of low dose computed tomography on lung cancer detection and mortality - an updated systematic review and meta-analysis
Submitted: April 2, 2022
Accepted: May 30, 2022
Published: June 21, 2022
Accepted: May 30, 2022
Abstract Views: 1341
PDF: 449
Supplementary: 92
Supplementary: 92
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Chest low dose computed tomography (LDCT) is reported to be a sensitive tool for the detection of lung cancer at asymptomatic stage, thus reducing mortality. The review assesses the effect of LDCT screening on all-cause mortality, lung cancer mortality and incidence rates. We conducted literature searches of PubMed, SCOPUS, and the Cochrane Library from inception through January 2020 to identify relevant studies assessing the diagnostic accuracy of LDCT for lung cancer. We used Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines for reporting this meta-analysis and review. The inclusion criteria were a) Randomized control trials, b) Comparing LDCT to any other form of screening or standard of care, and (c) Primary outcome studied: all-cause mortality, lung cancer-specific mortality, rate of early detection of lung cancer. A total of 11 studies encompassing 97,248 patients were included. When compared with controls (no screening or CXR), LDCT screening was associated with statistically significant reduction in lung cancer mortality (pooled RR 0.86; 95% CI 0.75-0.98); low heterogeneity was observed (I2= 27.86). However, LDCT screening was not associated with statistically significant reduction in all-cause mortality (RR =0.96; 95% CI: 0.92 -1.01). Notably, the LDCT screening was associated with statistically significant increase in lung cancer detection (RR =1.76; 95% CI: 1.14-2.72). LDCT screening has the potential to reduce mortality due to lung cancer among high-risk individuals. LDCT could be considered as a screening modality after careful assessment of other factors like prevalence of TB, proportion of high-risk population, cost, access and availability of LDCT.
National Cancer Institute [Internet]. Cancer Stat Facts: Lung and Bronchus Cancer. Accessed: 2019 Mar 28. Available from: https://seer.cancer.gov/statfacts/html/lungb.html
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
DOI: https://doi.org/10.3322/caac.21492
Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016;66:271-89.
DOI: https://doi.org/10.3322/caac.21349
De Koning HJ, Van Der Aalst CM, De Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med 2020;382:503-13.
DOI: https://doi.org/10.1056/NEJMoa1911793
The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
DOI: https://doi.org/10.1056/NEJMoa1102873
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PloS Med 2009;6:e1000097.
DOI: https://doi.org/10.1371/journal.pmed.1000097
Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
DOI: https://doi.org/10.1136/bmj.d5928
Gohagan J, Marcus P, Fagerstrom R, et al. Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: The Lung Screening Study of the National Cancer Institute. Chest 2004;126:114-21.
DOI: https://doi.org/10.1378/chest.126.1.114
Becker N, Motsch E, Gross ML, et al. Randomized study on early detection of lung cancer with MSCT in Germany: Results of the first 3 years of follow-up after randomization. J Thorac Oncol 2015;10:890-6.
DOI: https://doi.org/10.1097/JTO.0000000000000530
Blanchon T, Bréchot JM, Grenier PA, et al. Baseline results of the Depiscan study: A French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR). Lung Cancer 2007;58:50-8.
DOI: https://doi.org/10.1016/j.lungcan.2007.05.009
Paci E, Puliti D, Lopes Pegna A, et al. Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial. Thorax 2017;72:825-31.
DOI: https://doi.org/10.1136/thoraxjnl-2016-209825
Wille MMW, Dirksen A, Ashraf H, et al. Results of the randomized Danish lung cancer screening trial with focus on high-risk profiling. Am J Respir Crit Care Med 2016;193:542-51.
DOI: https://doi.org/10.1164/rccm.201505-1040OC
Pastorino U, Rossi M, Rosato V, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev 2012;21:308-15.
DOI: https://doi.org/10.1097/CEJ.0b013e328351e1b6
Infante M, Cavuto S, Lutman FR, et al. A randomized study of lung cancer screening with spiral computed tomography: Three-year results from the DANTE trial. Am J Respir Crit Care Med 2009;180:445-53.
DOI: https://doi.org/10.1164/rccm.200901-0076OC
Field JK, Duffy SW, Baldwin DR, et al. The UK lung cancer screening trial: A pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. Health Technol Assess (Rockv) 2016;20:1-146.
DOI: https://doi.org/10.3310/hta20400
Yang W, Qian F, Teng J, et al. Community-based lung cancer screening with low-dose CT in China: Results of the baseline screening. Lung Cancer 2018;117:20-6.
DOI: https://doi.org/10.1016/j.lungcan.2018.01.003
Huang KL, Wang SY, Lu WC, et al. Effects of low-dose computed tomography on lung cancer screening: A systematic review, meta-analysis, and trial sequential analysis. BMC Pulm Med 2019;19:1-11.
DOI: https://doi.org/10.1186/s12890-019-0883-x
Wood DE, Kazerooni EA, Baum SL, et al. Lung cancer screening, version 3.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2018;16:412-41.
DOI: https://doi.org/10.6004/jnccn.2018.0020
The International Early Lung Cancer Action Program Investigators, Henschke CI, Yankelevitz DF, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006;355:1763–71.
DOI: https://doi.org/10.1056/NEJMoa060476
Connell B, McKee B, McKee A, et al. Diagnostic workload generated by a low-dose CT lung screening program - The Lahey experience. Am J Respir Crit Care Med 2014;189:A6308.
Kumar V, Cohen JT, Van Klaveren D, et al. Risk-targeted lung cancer screening a cost-effectiveness analysis. Ann Intern Med 2018;168:161-9.
DOI: https://doi.org/10.7326/M17-1401
Shankar A, Saini D, Dubey A, et al. Feasibility of lung cancer screening in developing countries: Challenges, opportunities and way forward. Transl Lung Cancer Res 2019;8:S106-21.
DOI: https://doi.org/10.21037/tlcr.2019.03.03
How to Cite
Agrawal, Sumita, Akhil Dhanesh Goel, Nitesh Gupta, and Ayush Lohiya. 2022. “Role of Low Dose Computed Tomography on Lung Cancer Detection and Mortality - an Updated Systematic Review and Meta-Analysis”. Monaldi Archives for Chest Disease 93 (1). https://doi.org/10.4081/monaldi.2022.2284.
Copyright (c) 2022 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Govind Desai, Gopal Purohit, Hemant Borana, Kunal Deokar, Suresh Yogi, Comparison of efficacy of bedaquiline and moxifloxacin in drug resistant pulmonary tuberculosis. A prospective observational study , Monaldi Archives for Chest Disease: Vol. 93 No. 1 (2023)
- Fatemeh Khelghati, Fatemeh Nasirpour Seilakhori, Mehdi Goudarzi, Shima Malekloo, Amir Hashem Shahidi Bonjar, Hossein Goudarzi, Mohammad Javad Nasiri, Multidrug-resistant tuberculosis in Iran: a multicenter study , Monaldi Archives for Chest Disease: Early Access
- Surabhi Panduranga Kodical, Rishabh Roy, Deekshitha Shetty, Nandakumar UP, Rajesh V, Sharad Chand, Reshma Kolar, Praneetha Jain, Exploring factors influencing the health-related quality of life of tuberculosis patients: a WHOQOL-BREF-based study , Monaldi Archives for Chest Disease: Early Access
- Ankita Mandal, Ajay Kumar Verma, Sujit Kumar Kar, Jyoti Bajpai, Surya Kant, Santosh Kumar, Ram Avadh Singh Kushwaha, Rajiv Garg, Anand Srivastava, Darshan Kumar Bajaj, Sanjeev Kumar Verma, Shyam Chand Chaudhary, A cross-sectional study to determine the psychological distress among pulmonary tuberculosis patients during COVID-19 pandemic , Monaldi Archives for Chest Disease: Vol. 93 No. 1 (2023)
- Amos Lal, Ajay Kumar Mishra, Jamal Akhtar, Christoph Nabzdyk, Pneumothorax and pneumomediastinum in COVID-19 acute respiratory distress syndrome , Monaldi Archives for Chest Disease: Vol. 91 No. 2 (2021)
- Josuel Ora, Emanuela Prendi, Maria Laura Attinà, Mario Cazzola, Luigino Calzetta, Paola Rogliani, Efficacy of respiratory tele-rehabilitation in COPD patients: Systematic review and meta-analysis , Monaldi Archives for Chest Disease: Vol. 92 No. 4 (2022)
- Manju Bala, Akhlesh Rajpoot, Dinesh Chandra Punera, Suyash Singh Rathore, Hormonal harmony disrupted: hypothyroidism and diabetes mellitus in interstitial lung disease. An observational study , Monaldi Archives for Chest Disease: Early Access
- Malay Sarkar, Irappa Madabhavi, Nagaveni Kadakol, Oxygen-induced hypercapnia: physiological mechanisms and clinical implications , Monaldi Archives for Chest Disease: Vol. 93 No. 3 (2023)
- Diana Alexandra Gonçalves Pimenta, Renata Carvalho, Raquel Pereira, Rui Rolo, Lurdes Ferreira, Interstitial nephritis secondary to treatment with pembrolizumab, a rare complication in two patients with lung adenocarcinoma , Monaldi Archives for Chest Disease: Vol. 93 No. 2 (2023)
- Dario Amore, Umberto Caterino, Dino Casazza, Riccardo Ievoli, Pasquale Imitazione, Alessandro Saglia, Alessandro Izzo, Marco Rispoli, Carlo Curcio, Persistent alveolar air leak following pulmonary lobectomy: an old problem in a modern era , Monaldi Archives for Chest Disease: Vol. 93 No. 4 (2023)
<< < 21 22 23 24 25 26 27 28 29 30 > >>
You may also start an advanced similarity search for this article.
